Jun. 21, 2017

Novopyxis – The first start-up identified by LEO Science & Tech Hub

LEO Pharma announces an investment in the biotechnology company Novopyxis to support the development of an early-stage drug delivery device designed to increase the penetration of topical treatments in the skin.

The hand-held aerosol device will be clinically tested on people with alopecia, where there is a high need for alternative treatment options to painful steroid injections. Alopecia is an autoimmune disease leading to hair loss from all or some parts of the body, usually the scalp.

Read the press release

News from the hub

Aug. 2017 23 LEO Science & Tech Hub Announces Collaborations with MGH Wellman Center for Photomedicine to Explore Imaging Technology and Develop Microbiopsy Device

The Hub today announced two collaborative projects with The Wellman Center for Photomedicine at Massachusetts General Hospital. The Hub will provide research funding to support development of novel imaging technology with the laboratory led by Conor L. Evans, Ph.D., Assistant Professor, Harvard Medical School, and a disposable microbiopsy device with Walfre Franco, Ph.D., Instructor, and […]

Read more
Aug. 2017 10 LEO Science & Tech Hub is a finalist for the Newcomer category of Xconomy Awards

We are honored to announce that LEO Science & Tech Hub is a finalist for the Newcomer category of Xconomy Awards.

Read more